Clinical Trial Update: An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of a combination of JNJ-73763989, nucleos(t)ide analogs, and a PD-1 inhibitor in adults with chronic h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-73763989
• Nucleos(t)ide analogs
• PD-1 inhibitor

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2025-02-10